Abstract
BACKGROUND: Clinical researchers have often preferred to use a fixed effects model for the primary interpretation of a meta-analysis. Heterogeneity is usually assessed via the well known Q and I2 statistics, along with the random effects estimate they imply. In recent years, alternative methods for quantifying heterogeneity have been proposed, that are based on a 'generalised' Q statistic.
METHODS: We review 18 IPD meta-analyses of RCTs into treatments for cancer, in order to quantify the amount of heterogeneity present and also to discuss practical methods for explaining heterogeneity.
RESULTS: Differing results were obtained when the standard Q and I2 statistics were used to test for the presence of heterogeneity. The two meta-analyses with the largest amount of heterogeneity were investigated further, and on inspection the straightforward application of a random effects model was not deemed appropriate. Compared to the standard Q statistic, the generalised Q statistic provided a more accurate platform for estimating the amount of heterogeneity in the 18 meta-analyses.
CONCLUSIONS: Explaining heterogeneity via the pre-specification of trial subgroups, graphical diagnostic tools and sensitivity analyses produced a more desirable outcome than an automatic application of the random effects model. Generalised Q statistic methods for quantifying and adjusting for heterogeneity should be incorporated as standard into statistical software. Software is provided to help achieve this aim.
Original language | English |
---|---|
Pages (from-to) | 41 |
Journal | BMC Medical Research Methodology |
Volume | 11 |
DOIs | |
Publication status | Published - 2011 |
Keywords
- Analysis of Variance
- Clinical Trials as Topic
- Data Interpretation, Statistical
- Humans
- Meta-Analysis as Topic
- Neoplasms
- Randomized Controlled Trials as Topic
- Statistics as Topic